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Background: Several studies highlight curcumin’s benefit as a hypoglycemic agent, however; a limited number of
reports present the importance of curcumin in improvement of pancreatic islets in diabetes. The aim of the present
study is to evaluate the antidiabetic effect of a novel curcumin derivative and its effect on pancreatic islet
regeneration in type I diabetes-induced by STZ.
Materials and methods: Rats were divided into diabetic rats and diabetic rats treated orally with the novel
curcumin derivative (NCD) for 40 days. Fasting blood samples were withdrawn periodically from all rats to estimate
plasma glucose, insulin and C-peptide for 10 months. Histopathology was performed to allow the assessment of
pancreatic islet morphology. Insulin and CD105 were detected immunohistochemically.
Results: In diabetic rats, the plasma glucose, insulin and C-peptide levels remained within the diabetic range for
about 4 months, after which a gradual decrease in glucose and increase in insulin and C-peptide was observed,
which reached almost normal levels after 10 months. NCD treated diabetic rats showed significantly lowered plasma
glucose and increased plasma insulin and C-peptide levels. This was followed by a further significant decrease in
plasma glucose and increase in plasma insulin and C-peptide after two months from oral administration of the
NCD. The plasma insulin and C-peptide continued to increase for ten months reaching levels significantly higher
than the basal level. Histopathological examination of diabetic rat pancreas revealed absence of islets of Langerhans,
minimal adipose tissue infiltration and localized lymphocytic infiltrates. However, after 6 months of induction of
diabetes, rat pancreas showed the appearance of small well formed islets and positive insulin cells but no CD105
positive cells. NCD treated rats showed the appearance of primitive cell collections, large insulin positive cells and
CD105 positive cells in the adipose tissue infiltrating the pancreatic tissues. This was followed by the gradual
appearance of insulin positive cells in the islets while, CD 105 positive cells remained in the adipose tissue.
After 5 and 10 months from the onset of diabetes, rat pancreas showed, well developed larger sized islets with
disappearance of primitive cell collections and CD 105 positive cells. Also, insulin positive islets of variable size with
disappearance of insulin positive cells in adipose tissue were detected.
Conclusion: The NCD possesses antidiabetic actions and enhanced pancreatic islets regeneration.
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The prevalence of diabetes for all age-groups worldwide
was estimated to be 2.8% in 2000 and will rise to 4.4%
in 2030. The total number of people with diabetes is
projected to rise from 171 million in 2000 to 366 million
in 2030 [1].
Diabetes mellitus type I is an autoimmune disorder
caused by lymphocytic infiltration and β-cells destruction
within the pancreatic islets of Langerhans. The pancreatic
β-cells are lost in number and volume, leading to severe
permanent insulin deficiency [2].
Transplantation therapies for type 1 DM include whole
organ transplantation [3], transplantation of isolated islets
[4,5] and regeneration therapy [6]. Although the trans-
plantation of both a whole organ and isolated islets has
been successfully used in the clinical treatment of type 1
DM, a shortage of donors limits the widespread use of this
treatment modality. Additionally, the quality of a donor’s
pancreas is an important criterion for islet isolation [7].
Therefore, regeneration of pancreatic islets is certainly a
worthwhile therapeutic goal that would substantially
ameliorate diabetes and lessen its complications [8].
An alternative strategy to treat diabetes is the use of
various plant extracts and herbal biomolecules, due to
their hypoglycemic effects. Detailed investigation of these
biomolecules has revealed that some of them cause a
regeneration of β-cells, thus causing a reversal of diabetes
in human and non-human subjects [9-11].
Curcumin, the naturally occurring yellow pigment iso-
lated from the rhizomes of the plant Curcuma longa,
has been shown to possess antioxidant, anti-tumor, and
anti inflammatory properties [12,13]. At the cellular and
molecular levels, such effects for curcumin are mediated by
free-radical scavenging, up-regulation of defense proteins;
such as heme oxygenase-1 (HO) and reduced glutathione,
and suppression of pro-inflammatory/pro-apoptotic cyto-
kines/transcription factors; like TNF-α and NF-κB [14,15].
The potential of curcumin as a hypoglycemic agent
has been studied in animals [16,17]; yet with conflicting
results.
Abdel Aziz et al. [18] reported that insulin secretion,
HO-1 gene expression and HO activity were significantly
increased when rat isolated islets of Langerhans were
incubated in curcumin.
Abdel Aziz et al. [19] studied the antidiabetic effect of
a water soluble curcumin derivative (NCD) containing only
3.0% curcumin and its effects on diabetes-induced reactive
oxygen species (ROS) generation and lipid peroxidation in
experimental type- 1 diabetes mellitus. They proved that
the NCD had the ability to decrease plasma glucose and
increase plasma insulin levels significantly in diabetic rats.
NCD also improved the lipid profile and oxidative status,
proved by decreasing lipid peroxides (malondialdehyde) in
pancreas, liver & aorta.Because of the poor bioavailability of pure curcumin, a
new water soluble curcumin derivative was used in this
study.
The aim of the present study is to evaluate the antidia-
betic effect of a novel curcumin derivative (NCD) and its
effect on pancreatic islet regeneration in type I diabetes.
Materials and methods
This study was performed at the Unit of Biochemistry
and Molecular Biology at The Medical Biochemistry
Department, Faculty of Medicine, Cairo University, Egypt.
The curcumin derivative was presented free of charge
to the participating researchers as a personal nonprofit
scientific donation to help advancement of cooperation
in national medical research. The novel derivative, with
53.21% curcumin content is registered as international
patent protected by the rights of “The Patent Cooperation
Treaty” and are the personal property of their inventors
(PCT/EG2008/000044, WO 2010/057503, Regional phase
European Patent Application No. 08878223) [20]. The novel
water-soluble curcumin derivative with conserved natural
functional groups is [1,7-bis (5-carboxyphenylazo-4-hydroxy-
3-methoxyphenyl)1,6-heptadiene-3,5-dione]. This novel
water-soluble curcumin derivative with conserved natural
functional groups was developed in our laboratories through
covalent modification of the curcumin molecule on sites
remote from its natural functional groups.
Experimental animals
The experiments were performed on forty adult rats weigh-
ing 150 to 200 gm obtained from an inbred colony (Curl:
HEL1) at the Kasr Al-Aini animal experimental unit,
Faculty of Medicine, Cairo University. These animals were
kept in an environment with controlled temperature (25°C),
humidity (45-75%) and 12:12 h light:dark cycle. All animals
were fed ad libitum and had free access to water. All the
ethical protocols for animal treatment were followed and
supervised by the animal facilities, Faculty of Medicine,
Cairo University. All animal experiments received approval
from the Institutional Animal Ethics Committee.
Induction of diabetes mellitus
The animals were acclimatized for 1 week before initiation
of the experiment. Diabetes mellitus was induced in forty
rats by a single intraperitoneal injection of streptozotocin
(STZ) dissolved in 0.1M sodium citrate buffer, pH 4.5,
at a dose of 50 mg/kg. After 72 h, fasting blood glucose
levels were monitored and animals with blood glucose
levels >200 mg/dL were considered diabetic.
The forty rats were divided into two groups
Group I:Twenty diabetic rats as a control group
receiving no medications.
Table 1 Studied parameters at basal levels & after STZ-
induced diabetes
Parameter Basal (N=40) Diabetic (N=32) p value
Glucose (mg/dL) 92.83 ± 5.39 285.01 ± 54.64 <0.001
Insulin (μg/L) 4.68± 0.84 0.65 ±0.14 <0.001
C-peptide (ng/L) 2.89 ± 0.6 0.45 ± 0.11 <0.001
Data were presented as mean ± SD.
p value (significant difference by unpaired student-t test).
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curcumin derivative (NCD):
They received the NCD orally and in a daily dose of
150 mg/Kg body weight for forty days only starting from
the day after the onset of diabetes. (This dose is equivalent
to 80 mg/Kg body weight of pure curcumin).
Fasting blood samples were withdrawn periodically from
both groups from the tail vein to estimate plasma glucose,
insulin and C-peptide.
Plasma glucose estimation
Blood was collected from the tail vein into tubes containing
fluoride. Plasma samples were separated by centrifugation
at 3000 rpm for 10 min. Plasma glucose was measured
by the glucose oxidase method [21] using a commercially
available kit, Cat No 3728 (Diamond, Egypt).
Plasma insulin estimation
Plasma insulin was assayed by a commercially available
Enzyme-linked immunosorbent assay (ELISA) kit, Cat
No EIA - 2048 supplied by DRG Diagnostics (GmbH,
Germany) [22].
Assessment of C-peptide
C-peptide was assessed by a commercially available
Enzyme-linked immunosorbent assay (ELISA) kit,Cat
No 2725-300A supplied by Monobind Inc(Lake Forest,
Ca, USA) [23].
Histological and immunohistochemical analysis
Pancreata were excised, and then fixed in 10% neutral
buffered formalin. Tissues were then processed for paraffin
embedding, subsequent serial sectioning, and stained
with hematoxylin/eosin (H&E) to allow the assessment of
pancreatic islet morphology in the studied groups.
Insulin was detected immunohistochemically by mono-
clonal antibodies, Insulin Ab-6 (INSO4 + INSO5) mono-
clonal antibody, Cat No MS-1379-P : (200 μg/mL); Purified
antibody with BSA and azide); supplied by Thermo
Scientific (Fremont, USA).
CD 105 was detected immunohistochemically by mono-
clonal antibodies, CD 105/Endolgin monoclonal antibody,
Cat No MS –1290-P: (200 μg/mL); Purified antibody
with BSA and azide); supplied by Thermo Scientific
(Fremont, USA).
Statistical analysis
Unpaired Student's t-test was used for testing statistical
significance of difference between every 2 groups using
the PC software “Statistica version 8.0” of Statsoft Inc.,
USA. Paired Student’s t- test was used for testing statistical
significance of difference between time intervals in the
same group. Data were presented as mean ± SD. Thedifferences between groups were considered to be signifi-
cant at p <0.05.
Results
After induction of diabetes, 32 rats were remaining. These
rats were subgrouped into 16 diabetic and 16 diabetic
rats receiving the (NCD). Table 1 shows the studied pa-
rameters in the groups at basal level and after induction of
diabetes by STZ.
Plasma glucose levels
Figure 1 shows the changes in the fasting plasma glucose
levels in Group I and Group II rats.
The mean plasma glucose level of diabetic rats was
significantly increased (p < 0.001) compared to the basal
level. The rats showed hyperglycemia (plasma glucose >
200 mg/dL) 72 hrs after STZ treatment. The mean plasma
glucose level remained significantly elevated after forty
days after the onset of diabetes. This was followed by a
gradual decrease in the mean plasma glucose levels which
continued till 10 months after the onset of diabetes but
was still significantly higher (p < 0.001) than the basal level
(128.2 ± 8.9 mg/dL). The mean plasma glucose level of
diabetic rats receiving the NCD was significantly increased
(p < 0.001) compared to the basal level. The rats began
to show hyperglycemia (plasma glucose > 200 mg/dL) 72
hrs after STZ treatment. The NCD was administered for
40 days after the onset of diabetes. After these 40 days, the
mean plasma glucose of diabetic rats (151.51 ± 32.73 mg/dL)
showed a significant (p < 0.001) decrease compared to
the diabetic level (285.01 ± 54.64 mg/dL) which was
followed by a further significant (p < 0.001) decrease
(106.09 ± 8.61 mg/dL) after two months from the onset of
diabetes. This decrease in plasma glucose level was main-
tained for ten months but was still significantly higher
(p < 0.001) than the basal level (117.95 ± 9.05 mg/dL).
Plasma insulin levels
To gain insights into the insulin secretory capacity of
pancreatic islets and its relationship with plasma glucose,
we monitored fasting plasma insulin levels in diabetic rats
and diabetic rats receiving the NCD. Figure 2 shows the
changes in the fasting plasma insulin levels in Group I and
Group II rats. The mean plasma insulin level of diabetic
rats was significantly decreased (p < 0.001) compared to the
Figure 1 Changes in mean fasting plasma glucose levels in STZ-induced diabetic rats and diabetic rats receiving NCD.
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mean plasma insulin levels which increased significantly
after 4 months (1.12 ± 0.26 μg/L) and reached almost nor-
mal levels 10 months after the onset of diabetes (5 ± 0.6
μg/L). The mean plasma insulin level of diabetic rats
receiving the NCD was significantly decreased (p < 0.001)
compared to the basal level. After the 40 days of adminis-
tration of NCD, the mean plasma insulin level of diabetic
rats (4.09 ± 0.45 μg/L) showed a significant (p < 0.001) in-
crease compared to the diabetic level (0.65 ± 0.14 μg/L)
which was followed by a further significant (p < 0.001)
increase (5.26 ± 0.55 μg/L) after two months from the
onset of diabetes. The plasma insulin levels continued to
increase for ten months (14.11 ± 0.66 μg/L) reaching levels
significantly higher than the basal level (p < 0.001).
Plasma C-peptide levels
Figure 3 shows the changes in the fasting plasma C-peptide
levels in Group I and Group II rats: The mean plasmaFigure 2 Changes in mean fasting plasma insulin levels in STZ-induceC-peptide level of diabetic rats was significantly decreased
(p < 0.001) compared to the basal level. The mean plasma
C-peptide levels correspond to the fasting plasma insulin
levels in both diabetic rats and diabetic rats receiving
NCD.
Histopathological and immunochemical results
Histological examination of the H&E-stained paraffin
sections of rat pancreas subjected to streptozotocin (after
2 months from induction of diabetes) showed mostly
exocrine pancreatic tissue with no islets of Langerhans
and minimal adipose tissue infiltration (Figure 4A) and
localized lymphocytic collections(Figure 4B). Diabetic
rat pancreas stained with insulin antibody showed absence
of islets of Langerhans and no positivity with antiinsulin
in either pancreatic tissue or fat (Figure 4C). Diabetic
rat pancreas stained with CD 105 antibody showed no
evidence of CD 105 positive cells in either pancreatic tissue
or fat (Figure 4D).d diabetic rats and diabetic rats receiving NCD.
Figure 3 Changes in mean fasting plasma C-peptide levels in STZ-induced diabetic rats and diabetic rats receiving NCD.
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pancreas showed increased adipose tissue infiltration
and localized lymphocytic collections (Figure 5A) and
appearance of a small well-formed islet (Figure 5B).
While the diabetic rat pancreas stained with insulin
antibody showed a small well-formed islet secreting insulin
(Figure 5C), diabetic rat pancreas stained with CD 105
antibody showed no evidence of CD 105 positive cells in
either pancreatic tissue or fat (Figure 5D).Figure 4 Micrographs of diabetic rat pancreas after 2 months of indu
Eosin (H&E) showed mostly exocrine pancreatic tissue with no islets of Lan
lymphocytic collections (X200) (C) Diabetic rat pancreas stained with insuli
rat pancreas stained with CD 105 with no evidence of CD 105 positive cellHistological examination of the H&E-stained paraffin
sections of the pancreas of diabetic rats fed with NCD
after 2 months from the onset of diabetes showed pancre-
atic tissue infiltrated by adipose tissue with absence of islets
of Langerhans and collections of oval-round small cells
with minimal cytoplasm and dark nuclei in adipose tissue
(primitive cells) (Figure 6A). The rat pancreas also showed
few scattered larger cells with the appearance of lipoblasts
having more abundant bubbly pale cytoplasm scatteredction of diabetes. (A) Rat pancreas stained with Hematoxylin and
gerhans and minimal adipose tissue infiltration(X100) and (B) Localized
n antibody with no positive insulin secreting cells (X200) (D) Diabetic
s (X200).
Figure 5 Micrographs of diabetic rat pancreas after 6 months of induction of diabetes. (A) Rat pancreas stained with H&E showed
increased adipose tissue infiltration (star) and localized lymphocytic collections (arrows) (X40) (B) Rat pancreas with small well-formed
islet (star) (C) Diabetic rat pancreas stained with insulin antibody showed small well-formed islet (brown) secreting insulin. (X200)
(D) Diabetic rat pancreas stained with CD 105 antibody showed no evidence of CD 105 positive cells in either pancreatic tissue
or fat(X200).
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stained with insulin antibody showed few large insulin
positive cells in the cell collections in the adipose tissue
(Figure 6C) and cells are larger than the rest with abun-
dant cytoplasm with small round central dark nucleus
(Figure 6D) but no evidence of islets in pancreatic tissue
and no positivity for insulin (Figure 6E). The rat pancreas
stained with CD 105 antibody showed scattered positive
cells in the small blue cell collections in the adipose tissue
(Figure 6F and G), but no evidence of CD 105 positive
cells in pancreatic tissue (Figure 6H).
After 3 months from induction of diabetes the H&E-
stained paraffin sections of diabetic rats (fed NCD) dem-
onstrated more developed pancreatic tissue with evidence
of small sized islets of Langerhan (Figure 7A and B). The
pancreas also showed collections of oval – round small
primitive cells with minimal cytoplasm and dark nuclei in
nearby adipose tissue. More scattered larger cells with more
abundant pale foamy cytoplasm & central dark round
nuclei (lipoblastic cells) are found scattered within these
primitive cells (Figure 7C). Diabetic rat pancreas stained
with insulin antibody showed positive cells in islets
(Figure 7D and E) with more large insulin positive cells in
the cell collections in the adipose tissue (Figure 7F). Dia-
betic rat pancreas stained with CD 105 antibody showed
more positive cells in the small blue cell collections in the
adipose tissue mostly adjacent to pancreatic tissue(Figure 7G), but no evidence of CD 105 positive cells in
the pancreatic tissue (Figure 7H).
After 5 months from induction of diabetes the H&E-
stained paraffin sections of diabetic rats (fed NCD) showed
more developed pancreatic tissue with variable sized
well developed larger sized islets situated in a paravascular
pattern with no evidence of primitive cell collections
(Figure 8A and B). Diabetic rat pancreas stained with insu-
lin antibody showed insulin positive islets of variable
size (Figure 8C) and insulin negative adipose tissue
(Figure 8D). Diabetic rat pancreas stained with CD 105
antibody showed negative CD 105 in fat with an occasional
rare positive cell (Figure 8E and F).
Hematoxylin and Eosin sections of diabetic rat pancreas
(fed NCD) after 10 months from induction of diabetes
showed pancreatic tissue with increased amount of exo-
crine and endocrine components and many variable sized
and shaped islets of Langerhans (Figure 9A and B). Dia-
betic rat pancreas stained with insulin antibody showed
many variable sized & shaped islets with strong insulin
positivity (Figure 9C, D and E). Diabetic rat pancreas
stained with CD 105 antibody showed no positive
CD105 cells in pancreatic tissue or fat (Figure 9F).
Discussion
Effective management of diabetes is a pivotal global need
that is yet to be established. Modern drugs, including
Figure 6 Micrographs of diabetic rat pancreas (fed NCD) after 2 months from the onset of diabetes. (A) Rat pancreas stained with
H&E showed pancreatic tissue infiltrated by adipose tissue containing collections of primitive cells, but absence of pancreatic islets (X200)
and (B) Few scattered larger cells with the appearance of lipoblasts scattered within these primitive cells (X400) (C) & (D) Diabetic rat
pancreas stained with insulin antibody showed few large insulin positive cells in the adipose tissue with no evidence of islets in pancreatic
tissue and no positivity for insulin (X200 and X1000,respectively) (E) Diabetic rat pancreas stained with insulin antibody showed no evidence
of islets in pancreatic tissue and no insulin positivity (X200) (F) (X200) & (G) (X1000)Diabetic rat pancreas stained with CD 105 antibody
showed positive CD105 cells in the adipose tissue. (H) Diabetic rat pancreas stained with CD 105 antibody showed no evidence of CD 105
positive cells in pancreatic tissue (X200).
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glucose level only when they are regularly administered,
but these treatments are tedious and tend to pose several
clinical challenges [24]. However, medicinal herbs may offer
a similar degree of efficacy without so many troublesome
side effects.The effectiveness of curcumin in reducing secondary
complications in STZ induced diabetic animals has been
previously reported [25]. Moreover, curcumin has been
demonstrated in prevention of isolated beta cell death
and dysfunction induced by STZ [26,27]. Several studies
also highlight its benefit as a hypoglycemic agent [16-20]
Figure 7 Micrographs of diabetic rat pancreas (fed NCD) stained with after 3 months from the onset of diabetes. (A) & (B) Rat pancreas
stained with H&E showed more developed pancreatic tissue with evidence of small sized islets of Langerhan (X100 and X1000, respectively) (C)
Collections of primitive cells in nearby adipose tissue and more abundant lipoblasts (X1000). (D) (X200) & (E) (X400) Diabetic rat pancreas stained
with insulin antibody showed positive insulin producing cells in islets. (F) More large insulin positive cells in the cell collections in the adipose
tissue (X1000) (G) Diabetic rat pancreas stained with CD 105 antibody showed more positive cells in the adipose tissue mostly adjacent to
pancreatic tissue (X1000) and (H) no evidence of CD 105 positive cells in the pancreatic tissue (X400).
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ance of curcumin in improvement of pancreatic islets in
diabetes. In the present study, we would like to evaluate
the antidiabetic effect of a novel curcumin derivative and
its effect on pancreatic islet regeneration in type I dia-
betes-induced by STZ.
Diabetes in this study was induced by STZ, an alkylat-
ing agent that causes DNA damage in beta-cells andsubsequent inhibition of insulin biosynthesis and secretion
[28]. Our data showed that induction of diabetes by STZ
led to a significant increase of plasma glucose and a
significant decrease in plasma insulin and C-peptide
levels compared to the basal levels. It has been reported
that destruction of β-cells by streptozotocin remains as
such incomplete that the resulting rats are hyperglycemic
but do not die [29]. This view goes well with the currently
Figure 8 Micrographs of diabetic rat pancreas (fed NCD) after 5 months from the onset of diabetes. (A) (X200) & (B) (X400):
Diabetic rat pancreas stained with H & E showed more developed pancreatic tissue with variable sized well developed larger sized
islets situated in a paravascular pattern. (C) Diabetic rat pancreas stained with insulin antibody showed insulin positive islets of
variable size (X200) (D) Diabetic rat pancreas stained with insulin antibody showed insulin negative adipose tissue (X200) (E) & (F)
Diabetic rat pancreas stained with CD 105 antibody showed negative CD 105 in fat with an occasional rare positive cell (X1000
and X400,respectively).
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mice.
Our results demonstrated that the plasma glucose levels
in diabetic rats decreased gradually while the insulin and
C-peptide levels increased gradually although still, within
the diabetic range until 4 months after induction of
diabetes. This was followed by a more significant decrease
in plasma glucose and a more significant increase in
plasma insulin and C-peptide levels which continued for
10 months after induction of diabetes reaching almost
normal basal levels.
These results could be explained by the fact that insulin-
secreting pancreatic beta-cells proliferate in response to
increasing demand for insulin and also after physiological
injury [30-32]. It is generally accepted that beta-cells have
a finite life span and that dying beta-cells are continuously
replaced [33,34]. Indeed, there are clinical case-reports ofbeta-cell regeneration enabling the complete recovery from
type 1 diabetes [35]. However, in the majority of patients,
the reported level of recovery is not sufficient to cure, or
even maintain glucose homeostasis [30,32].
Several reports of functional pancreatic beta-cell regen-
eration in murine models [36,37] has generated much
excitement and controversy [38,39].
Curcumin is a naturally occurring yellow pigment pow-
der extracted from the roots of the Curcuma longa plant
(Turmeric). Curcumin has been shown to exhibit anti
inflammatory [40], antioxidant [12], anti-tumor [41] and
anti-diabetic activities [16,17]. Furthermore, curcumin
has been demonstrated in protecting isolated islet against
streptozotocin (STZ)-induced oxidative stress by scaven-
ging free radicals [26]. However, its efficacy in ameliorative
pancreatic islets from STZ-induced diabetic mice is still
lacking.
Figure 9 Micrographs of diabetic rat pancreas (fed NCD) after 10 months from the onset of diabetes. (A) (X100) & (B) (X400) Diabetic rat
pancreas stained with H&E showed pancreatic tissue with increased amount of exocrine and endocrine components and many variable sized and
shaped islets of Langerhans. (C) (X40), (D) (X200) & (E) (X1000) Diabetic rat pancreas stained with insulin antibody showed many variable sized &
shaped islets with strong insulin positivity(brown) (F) Diabetic rat pancreas stained with CD 105 antibody showed no positive CD105 cells in
pancreatic tissue or fat (X100).
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rats significantly reduced the plasma glucose, significantly
increased plasma insulin and C-peptide compared to
the diabetic rats. The plasma insulin and C-peptide levels
continued to increase for ten months from the onset of
diabetes reaching levels significantly higher than the
basal level.
The results of the current study are in accordance with
the work of others who reported that administration of
oral curcumin to diabetic mice or rats fed with curcumin
resulted in a significant decrease in the blood glucose
level when compared with the diabetic group [19,42-44].
Histopathological examination of diabetic rat pancreas
2 months after induction of diabetes, revealed mostly
exocrine pancreatic tissue with no islets of Langerhans,
minimal adipose tissue infiltration and localized lympho-
cytic infiltrates. Also, pancreatic tissues and adipose tissues
showed no evidence of insulin or CD105 positive cells.Diabetes type I is an autoimmune disease that is char-
acterized by selective destruction of insulin-producing
β-cells found in the pancreatic islets of Langerhans [45].
The development of diabetes is initiated with insulitis, in
which leukocytes migrate to and invade the islets. This is
followed by an overt, insulin deficient diabetes phase that
is distinguished by destruction of the majority of β-cell
[2]. However, after 6 months of induction of diabetes,
rat pancreas showed the appearance of small well formed
islets and positive insulin cells but no CD105 positive
cells. This resulted in the observed gradual increase in
plasma insulin and decrease in plasma glucose levels,
suggesting that the expansion of beta cell mass compen-
sated for increased insulin demands in order to control
blood glucose homeostasis [46].
Each tissue or organ is believed to contain a small
sub-population of cells that is capable of self-renewal
and has the ability to give rise to each mature cell type
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cells might be pancreatic stem cells. While several studies
have shown the existence of pancreatic stem cells [48-50],
these cells have not yet been isolated from the pancreas in
a pure form.
Early studies by Slack [51] indicated the failure of islet
regeneration following treatment with streptozotocin or
alloxan and suggested that these drugs target, in addition
to the differentiated β-cells, the potential stem or transit
cells. Contrary to this report, more recent studies have
shown that streptozotocin does not destroy the intra-islet
stem cell reserve in experimentally-diabetic animals [52].
In support, Ianus et al. [53] demonstrated that bone
marrow cells can differentiate into functionally competent
pancreatic β-cells; thereby rationalizing for the cell-based
approach in treatment of diabetes.
Histopatological examination of diabetic rat pancreata
(fed NCD for 40 days) was performed after 2, 3, 5 and
10 months from the onset of diabetes.
Two months from the onset of diabetes, histopathological
examination of rat pancreas showed the appearance of
collections of primitive cells in adipose tissue infiltrating
the pancreas. Also, large insulin positive cells were found
in the adipose tissue with absence of islets in pancreatic
tissue and no positivity for insulin. To identify these cells,
rat pancreas was stained with CD 105 antibody which
showed scattered positive cells in the small blue cell
collections in the adipose tissue while no evidence of CD
105 positive cells in pancreatic tissues was observed.
Crisan et al. [54] have found that multipotent mesen-
chymal stem cells exist in many different human organs.
To support this fact, it has been shown that MSCs are
not confined to bone marrow and can also be found in
placenta, dental pulp, tendons, skeletal muscle, fat, um-
bilical cord blood and amniotic fluid [55-59].
After 3 months from the onset of diabetes, rat pan-
creas showed more developed pancreatic tissue with evi-
dence of small sized islets of Langerhan. Collections of
small primitive cells in nearby adipose tissue were also
seen. Rat pancreas stained with insulin antibody showed
positive cells in islets. More large insulin positive cells
were found in the cell collections in the adipose tissue.
Staining with CD 105 antibody showed more positive
cells in the adipose tissue mostly adjacent to pancreatic
tissue. However, rat pancreas stained with CD 105 anti-
body showed no evidence of CD 105 positive cells in the
pancreatic tissue.
After 5 months from the onset of diabetes, rat pancreas
showed more developed pancreatic tissue with variable
sized well developed larger sized islets situated in a
paravascular pattern with disappearance of primitive
cell collections. Rat pancreas stained with insulin antibody
showed insulin positive islets of variable size with dis-
appearance of insulin positive cells in adipose tissue. Ratpancreas stained with CD 105 antibody showed negative
CD 105 in fat with an occasional rare positive cell.
After 10 months from the onset of diabetes, rat pancreas
showed pancreatic tissue with increased amount of
exocrine and endocrine components and many variable
sized and shaped islets of Langerhans. Staining with insu-
lin antibody showed many variable sized & shaped islets
with strong insulin positivity and no CD 105 positive cells
in pancreatic tissue or fat.
Histopatholgical and immunohistochemical examination
reported the appearance of stem cells in the adipose tissue
infiltrating the pancreatic tissues in diabetic rat receiving
the NCD. These cells were positive for CD105. This co-
incides with the work of Moniri et al. [60] who reported
that pancreas-derived MSCs exhibited positive expression
of CD44, CD73, CD95, and CD105 and Xiao-Jie et al. [61]
who reported that CD105 can be used as a relatively
specific marker for the selection of adipose-derived stem
cells.
It is known that regeneration processes are needed to
maintain the critical cell mass which is necessary to
maintain organ homeostasis. The potential of replication
is limited in the case of pancreatic β-cells. However, in a
population of normal adult pancreatic islet cells, the
number of β-cells actually undergoing cell division is
small, measured to be between 0.5 and 2% [62]. Only in
recent years has it been revealed that the pancreas can
indeed undergo repair following damage, a process known
today as regeneration.
A study by Yamamoto et al. [63] showed that the fetal
pancreas treated with STZ has the ability to regenerate
β-cells in vivo. Once it was established that pancreas
can regenerate, researchers started to look at the factors
and stimuli that instruct pancreatic tissue to undergo
regeneration.
The pancreas has been reported as the organ with the
lowest levels of antioxidant enzymes; consequently,
pancreatic β-cells are exceptionally vulnerable to detri-
mental actions of oxidative stress [64]. The cytotoxic,
diabetogenic action of streptozotocin is mediated mostly
by reactive oxygen species [65]. Accordingly, curcumin,
which possess antioxidant [12] and anti inflammatory
properties [13] could play a role in reversing the effects
of experimental streptozotocin-induced diabetes.
Curcumin abates oxidative stress due to reactive oxygen
species and lipid-peroxidation by reducing hyperglycemia,
and enhancing endogenous antioxidant machinery (gluta-
thione peroxidase, catalase, superoxide-dismutase, and
reduced glutathione, and GSH). Abdel Aziz et al. [18,19,44]
studied the antidiabetic and antioxidant effects of curcumin
and NCD on isolated pancreatic islets and in type -1
diabetes. These studies reported that NCD increased HO-1
gene expression and HO activity in the pancreas. NCD also
improved the oxidative status, protected and enhanced
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peroxides (malondialdehyde) in pancreas & liver.
This certainly protects residual pancreatic islets and
newly bone marrow transplantation-generated ones against
cellular damage evoked by reactive oxygen species or
advanced-glycation end products [66,67].
In addition, curcumin obliterates inflammation and
immune response; as evident by its ability to suppress
production of the cytokines, tumor necrosis factor (TNF)-α
and interleukin (IL)-1β [68]. This certainly creates a
favorable systemic and pancreatic environment to foster
bone marrow transplantation and islet neogenesis. Ac-
cordingly, administration of curcumin; as an established
anti-inflammatory and immune modulatory drug; would
likely boost and preserve the process of islet regener-
ation; which was evidently proven true in this study.
Previous studies have indicated that cucumin plays an
important role in regulation of cell differentiation. Thaloor
et al., (1999) [69] demonstrated that curcumin is involved
in stimulation of muscle regeneration after traumatic in-
jury by directly inducing proliferation and differentiation
of muscle precursor cells Other studies have also shown
that curcumin induces neurogenesis, synaptogenesis and
migration of neural progenitor cells in vitro and in vivo
[70,71]. Recently, Mujoo et al. (2012) [72] reported that
curcumin induces differentiation of embryonic stem cells
through possible modulation of nitric oxide –cyclic GMP
pathway.
Conclusion
Our current data suggest that the NCD can significantly
ameliorate experimental type 1diabetes. Our study provides
clear evidence of pancreatic islets regeneration in response
to treatment of diabetic rats with the NCD for forty days.
This could be attributed to the anti –inflammatory and
antioxidant effects of curcumin and thus creates a favorable
systemic and pancreatic environment to foster islet neo-
genesis. Also, the role of curcumin in cell proliferation
and differentiation of stem cells may be involved.
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